Human albumin (HA) is a blood plasma protein produced in the liver. It constitutes about 60% of plasma proteins and is a physiological plasma-expander. However, its limited availability and high cost make it essential to define recommendations for its appropriate use, as an alternative to other therapeutic strategies including solutions of crystalloids and non-protein colloids. According to all official recommendations, the choice to use albumin rather than an artificial colloid strictly depends on the clinical situation of the patient1–6. HA is also used in all cases in which there is a contraindication to the use of non-protein colloids7. Based on clinical evidence, the 2009 guidance document of the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI)7 recommends the use of HA in acute conditions, which call for blood volume expansion and maintenance of adequate blood flow, as well as in some chronic conditions of low serum albumin levels. “There are some widely shared and fully agreed indications for the appropriate use of human albumin and indications that are occasionally appropriate, that is, when other criteria are fulfilled”7. In addition, in haemorrhagic shock HA should only be used as a second choice [i.e. when solutions of crystalloids or non-protein colloids (first choice treatment) have already been used at maximum doses without having produced a clinically adequate response] and in cases in which non-protein colloids are contraindicated7.